ATLAS fair value
ATLAS has no fair value for this stock today.
Eocene stock price today, ATLAS forecast and fair value
Healthcare · Biotechnology · NASDAQ
Prices as of Oct 26, 2026 · USD
ATLAS has no fair value for this stock today.
46%
that it ends higher than today in 21 sessions
ATLAS's own quantitative analysis, all in one place.
Plans from €3.99 a month.
ATLAS's model gives Eocene a 46% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between $2.71 and $3.53; in 9 out of 10, between $2.15 and $4.45. Estimated annual volatility is 72%.
ATLAS does not publish a fair value for EOCN right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks EOCN has traded between $2.33 and $12.32. Today it is 74.4% below that high and 35% above its low.
Its beta is 0.66: it tends to move less than the market.
Eocene Ltd. is an Israel-based biopharmaceutical and medtech company focused on gastrointestinal disease management and related therapeutic areas. The company develops pharmaceutical and device-based solutions for conditions such as liver disorders, gastrointestinal oncology, and colorectal care.
Want to see everything about Eocene?
Get started →Plans from €3.99 a month.
Other companies in the same line of business:
Eocene Ltd. is an Israel-based biopharmaceutical and medtech company focused on gastrointestinal disease management and related therapeutic areas. The company develops pharmaceutical and device-based solutions for conditions such as liver disorders, gastrointestinal oncology, and colorectal care.
46%: close to a coin flip. In half of the simulated outcomes, EOCN ends the month between $2.71 and $3.53.
Eocene's market capitalization is $3.0M. We do not show a P/E because it has no positive earnings to base one on.
ATLAS estimates annual volatility at 72%. In a typical month, half of the outcomes end between $2.71 and $3.53.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer
ATLAS Signals
The week in the market, three stocks on ATLAS’s radar and what comes next. Get it every Monday.
By subscribing you agree to receive ATLAS Signals by email every Monday. You can unsubscribe with one click at any time. Privacy